Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial.

about

Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial.

Item

http://www.wikidata.org/entity/Q47691053

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Metronidazole or Rifaximin for ...... : A Randomized Clinical Trial.

@en

Metronidazole or Rifaximin for ...... : A Randomized Clinical Trial.

@nl

type

Item

label

Metronidazole or Rifaximin for ...... : A Randomized Clinical Trial.

@en

Metronidazole or Rifaximin for ...... : A Randomized Clinical Trial.

@nl

prefLabel

Metronidazole or Rifaximin for ...... : A Randomized Clinical Trial.

@en

Metronidazole or Rifaximin for ...... : A Randomized Clinical Trial.

@nl

P1476

Metronidazole or Rifaximin for ...... e: A Randomized Clinical Trial

@en

P2093

Aleksandra Banaszkiewicz

http://www.w3.org/2001/XMLSchema#string

Dominika Lachowicz

http://www.w3.org/2001/XMLSchema#string

Marcin Banasiuk

http://www.w3.org/2001/XMLSchema#string

P2860

Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.

Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Antibiotics for Treatment of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.

In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.

Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population.

Disproportionate rise in Clostridium difficile-associated hospitalizations among US youth with inflammatory bowel disease, 1997-2011.

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

P304

2209-2214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MIB.0000000000001249

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hanna Pituch

Piotr Albrecht

Agnieszka Gawrońska

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29084080

http://www.w3.org/2001/XMLSchema#string